4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-22-026890
Chief Financial Officer sold 697 shares at $11.75 ($8,190)
- Chief Financial Officer acquired 2,886 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
van Houte Hans · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-04-30 | Exercise or conversion : show line 1 in the form | +2,886 | 2,886 | D | ||
| 2022-05-02 | Sale : show line 2 in the form | −697 | $11.75 | $8,190 | 2,189 | D |
| Open-market sales · 697 sh · avg $11.75 · $8,190 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-04-30 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −2,886 | 43,291 | D |
Loading xslF345X03/doc4.xml…